Patents by Inventor Baoming Jiang
Baoming Jiang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11786589Abstract: A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine.Type: GrantFiled: June 16, 2021Date of Patent: October 17, 2023Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Baoming Jiang, Roger I. Glass, Yuhuan Wang, Jon Gentsch
-
Patent number: 11759513Abstract: Attenuated G9P[6] rotavirus is disclosed herein. In some embodiments, pharmaceutical compositions are disclosed that include an attenuated G9P[6] rotavirus, or a component thereof. These compositions can be used to induce an immune response, such as a protective immune response, to a rotavirus. The compositions can be used as vaccines, such as for children (infants), for example in a prime boost strategy.Type: GrantFiled: October 29, 2021Date of Patent: September 19, 2023Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Baoming Jiang, Yuhuan Wang
-
Publication number: 20220040288Abstract: Attenuated G9P[6] rotavirus is disclosed herein. In some embodiments, pharmaceutical compositions are disclosed that include an attenuated G9P[6] rotavirus, or a component thereof. These compositions can be used to induce an immune response, such as a protective immune response, to a rotavirus. The compositions can be used as vaccines, such as for children (infants), for example in a prime boost strategy.Type: ApplicationFiled: October 29, 2021Publication date: February 10, 2022Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICInventors: Baoming Jiang, Yuhuan Wang
-
Patent number: 11235054Abstract: Stable, immunogenic combination vaccine(s) comprising a mixture of antigens for prevention and prophylaxis of infections caused by Rotavirus, Poliomyelitis virus, Haemophilus influenzae, Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis and Hepatitis B virus. A multivalent combination vaccine comprises i) significantly dose-reduced Salk-IPV or Sabin-IPV (IPV) antigens prepared by methods of formaldehyde inactivation and alum hydroxide adsorption resulting in maximum D-antigen recovery; ii) Injectable heat inactivated Rotavirus antigen(s) providing broad cross-protective immunity among human rotavirus strains; iii) Hib PRP-carrier protein conjugate having improved stability and immunogenicity; iv) whole cell pertussis antigen with improved immunogenicity and stability; and v) Homogenous fractions of Diphtheria and Tetanus toxoids.Type: GrantFiled: August 24, 2017Date of Patent: February 1, 2022Assignees: Serum Institute of India Private Limited, The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Rajeev Mhalasakant Dhere, Sambhaji Shankar Pisal, Jagdish Kamalaji Zade, Rajendra Narayan Sabale, Ravindra Bapurao Kadam, Abhijeet Sanjeev Kamble, Baoming Jiang, Roger Glass
-
Patent number: 11185581Abstract: Attenuated G9P[6] rotavirus is disclosed herein. In some embodiments, pharmaceutical compositions are disclosed that include an attenuated G9P[6] rotavirus, or a component thereof. These compositions can be used to induce an immune response, such as a protective immune response, to a rotavirus. The compositions can be used as vaccines, such as for children (infants), for example in a prime boost strategy.Type: GrantFiled: December 17, 2019Date of Patent: November 30, 2021Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Baoming Jiang, Yuhuan Wang
-
Publication number: 20210353739Abstract: Methods of thermally inactivating a rotavirus are provided according to the present invention which include exposing the rotavirus to a temperature in the range of about 50° C.-80° C., inclusive, for an incubation time sufficient to render the rotavirus incapable of replication or infection. The thermally inactivated rotavirus is antigenic and retains a substantially intact rotavirus particle structure. Vaccine compositions and methods of vaccinating a subject against rotavirus are provided which include generation and use of thermally inactivated rotavirus.Type: ApplicationFiled: July 26, 2021Publication date: November 18, 2021Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Baoming Jiang, Roger I. Glass, Jean-Francois Saluzzo
-
Publication number: 20210308254Abstract: A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine.Type: ApplicationFiled: June 16, 2021Publication date: October 7, 2021Applicant: TED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicesInventors: Baoming Jiang, Roger I. Glass, Yuhuan Wang, Jon Gentsch
-
Patent number: 11103572Abstract: Methods of thermally inactivating a rotavirus are provided according to the present invention which include exposing the rotavirus to a temperature in the range of about 50° C.-80° C., inclusive, for an incubation time sufficient to render the rotavirus incapable of replication or infection. The thermally inactivated rotavirus is antigenic and retains a substantially intact rotavirus particle structure. Vaccine compositions and methods of vaccinating a subject against rotavirus are provided which include generation and use of thermally inactivated rotavirus.Type: GrantFiled: December 20, 2019Date of Patent: August 31, 2021Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Baoming Jiang, Roger I. Glass, Jean-Francois Saluzzo
-
Patent number: 11065327Abstract: A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine.Type: GrantFiled: November 1, 2019Date of Patent: July 20, 2021Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Baoming Jiang, Roger I. Glass, Yuhuan Wang, Jon Gentsch
-
Publication number: 20200121782Abstract: Methods of thermally inactivating a rotavirus are provided according to the present invention which include exposing the rotavirus to a temperature in the range of about 50° C.-80° C., inclusive, for an incubation time sufficient to render the rotavirus incapable of replication or infection. The thermally inactivated rotavirus is antigenic and retains a substantially intact rotavirus particle structure. Vaccine compositions and methods of vaccinating a subject against rotavirus are provided which include generation and use of thermally inactivated rotavirus.Type: ApplicationFiled: December 20, 2019Publication date: April 23, 2020Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Baoming Jiang, Roger I. Glass, Jean-Francois Saluzzo
-
Publication number: 20200121781Abstract: Attenuated G9P[6] rotavirus is disclosed herein. In some embodiments, pharmaceutical compositions are disclosed that include an attenuated G9P[6] rotavirus, or a component thereof. These compositions can be used to induce an immune response, such as a protective immune response, to a rotavirus. The compositions can be used as vaccines, such as for children (infants), for example in a prime boost strategy.Type: ApplicationFiled: December 17, 2019Publication date: April 23, 2020Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICInventors: Baoming Jiang, Yuhuan Wang
-
Publication number: 20200054735Abstract: A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine.Type: ApplicationFiled: November 1, 2019Publication date: February 20, 2020Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Baoming Jiang, Roger I. Glass, Yuhuan Wang, Jon Gentsch
-
Patent number: 10556001Abstract: Methods of thermally inactivating a rotavirus are provided according to the present invention which include exposing the rotavirus to a temperature in the range of about 50° C.-80° C., inclusive, for an incubation time sufficient to render the rotavirus incapable of replication or infection. The thermally inactivated rotavirus is antigenic and retains a substantially intact rotavirus particle structure. Vaccine compositions and methods of vaccinating a subject against rotavirus are provided which include generation and use of thermally inactivated rotavirus.Type: GrantFiled: October 4, 2017Date of Patent: February 11, 2020Assignee: The united States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Baoming Jiang, Roger I. Glass, Jean-Francois Saluzzo
-
Patent number: 10548970Abstract: Attenuated G9P[6] rotavirus is disclosed herein. In some embodiments, pharmaceutical compositions are disclosed that include an attenuated G9P[6] rotavirus, or a component thereof. These compositions can be used to induce an immune response, such as a protective immune response, to a rotavirus. The compositions can be used as vaccines, such as for children (infants), for example in a prime boost strategy.Type: GrantFiled: September 28, 2016Date of Patent: February 4, 2020Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICESInventors: Baoming Jiang, Yuhuan Wang
-
Patent number: 10500269Abstract: A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine.Type: GrantFiled: April 18, 2018Date of Patent: December 10, 2019Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicesInventors: Baoming Jiang, Roger I. Glass, Yuhuan Wang, Jon Gentsch
-
Publication number: 20190175722Abstract: Stable, immunogenic combination vaccine(s) comprising a mixture of antigens for prevention and prophylaxis of infections caused by Rotavirus, Poliomyelitis virus, Haemophilus influenzae, Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis and Hepatitis B virus. A multivalent combination vaccine comprises i) significantly dose-reduced Salk-IPV or Sabin-IPV (IPV) antigens prepared by methods of formaldehyde inactivation and alum hydroxide adsorption resulting in maximum D-antigen recovery; ii) Injectable heat inactivated Rotavirus antigen(s) providing broad cross-protective immunity among human rotavirus strains; iii) Hib PRP-carrier protein conjugate having improved stability and immunogenicity; iv) whole cell pertussis antigen with improved immunogenicity and stability; and v) Homogenous fractions of Diphtheria and Tetanus toxoids.Type: ApplicationFiled: August 24, 2017Publication date: June 13, 2019Inventors: Rajeev Mhalasakant DHERE, Sambhaji Shankar PISAL, Jagdish Kamalaji ZADE, Rajendra Narayan SABALE, Ravindra Bapurao KADAM, Abhijeet Sanjeev KAMBLE, Baoming JIANG, Roger GLASS
-
Publication number: 20190091325Abstract: Attenuated G9P[6] rotavirus is disclosed herein. In some embodiments, pharmaceutical compositions are disclosed that include an attenuated G9P[6] rotavirus, or a component thereof. These compositions can be used to induce an immune response, such as a protective immune response, to a rotavirus. The compositions can be used as vaccines, such as for children (infants), for example in a prime boost strategy.Type: ApplicationFiled: September 28, 2016Publication date: March 28, 2019Applicant: THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICESInventors: Baoming Jiang, Yuhuan Wang
-
Publication number: 20180236060Abstract: A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine.Type: ApplicationFiled: April 18, 2018Publication date: August 23, 2018Inventors: Baoming Jiang, Roger I. Glass, Yuhuan Wang, Jon Gentsch
-
Patent number: 9974851Abstract: Immunogenic pharmaceutical compositions including a live, attenuated human rotavirus or an inactivated human rotavirus are provided which are useful for inducing an immunological response against the rotavirus in a subject. Methods of inducing an immunological response to a rotavirus in a subject are provided by administering an immunogenic pharmaceutical composition including a live, attenuated human rotavirus or an inactivated human rotavirus described herein.Type: GrantFiled: July 1, 2016Date of Patent: May 22, 2018Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Baoming Jiang, Roger I. Glass, Yuhuan Wang, Jon Gentsch
-
Publication number: 20180028644Abstract: Methods of thermally inactivating a rotavirus are provided according to the present invention which include exposing the rotavirus to a temperature in the range of about 50° C.-80° C., inclusive, for an incubation time sufficient to render the rotavirus incapable of replication or infection. The thermally inactivated rotavirus is antigenic and retains a substantially intact rotavirus particle structure. Vaccine compositions and methods of vaccinating a subject against rotavirus are provided which include generation and use of thermally inactivated rotavirus.Type: ApplicationFiled: October 4, 2017Publication date: February 1, 2018Applicant: The united States of America, as represented by the Secretary, Department of Health and Human ServInventors: Baoming Jiang, Roger I. Glass, Jean-Francois Saluzzo